Who Supplies Fentanyl to India from GREECE

Importing finished pharmaceutical formulations containing Fentanyl into India requires compliance with the Central Drugs Standard Control Organization (CDSCO) regulations. The importing company must obtain an Import License in Form 10 from the Directorate General of Foreign Trade (DGFT). Additionally, the product must be registered with CDSCO, which involves submitting Form 40 along with necessary documents such as a Free Sale Certificate, Good Manufacturing Practice (GMP) certificate, and a Certificate of Pharmaceutical Product (CoPP). The registration process typically takes several months, depending on the completeness of the application and the regulatory review process. For formulations containing controlled substances like Fentanyl, additional approvals from the Narcotics Commissioner may be required. The importer must also ensure compliance with the Narcotic Drugs and Psychotropic Substances Act, 1985, and associated rules.

Upon arrival in India, each batch of imported Fentanyl formulations must undergo quality testing at a CDSCO-approved laboratory. The importer is required to submit a Certificate of Analysis (CoA) for each batch, demonstrating compliance with Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, must be provided to ensure the product's efficacy and safety under Indian climatic conditions. Customs drug inspectors conduct port inspections to verify the authenticity of the documentation and the quality of the product. If a batch fails to meet the required standards, it may be subject to rejection, re-exportation, or destruction, depending on the severity of the non-compliance.

Between 2024 and 2026, the Indian government has implemented several regulatory updates affecting the import of finished pharmaceutical formulations. The Production Linked Incentive (PLI) scheme has been expanded to encourage domestic manufacturing, potentially impacting the volume of imports. Bilateral agreements with Greece have been established to facilitate smoother trade, including mutual recognition of Good Manufacturing Practices (GMP) and streamlined customs procedures. These agreements aim to enhance the efficiency and safety of pharmaceutical imports, including those containing controlled substances like Fentanyl.

India imports finished Fentanyl formulations to meet the demand for pain management, particularly in oncology and palliative care. The imported formulations often include patented or branded products and specific dosage forms not readily available domestically. While India has a growing domestic pharmaceutical industry, certain specialized formulations and dosages necessitate imports. The market size for Fentanyl formulations in India is substantial, with a steady increase in demand due to the rising prevalence of chronic pain conditions.

The import of Fentanyl formulations under HS Code 30049099 is subject to a Basic Customs Duty (BCD) of 10%. Additionally, a Social Welfare Surcharge (SWS) of 10% on the BCD is applicable. Integrated Goods and Services Tax (IGST) is levied as per the prevailing rates, which vary based on the product classification and applicable notifications. There are no specific exemptions or concessional duties for imports from Greece under this HS code. The total landed duty percentage combines these components, affecting the final cost of imported goods.

India sources Fentanyl formulations from Greece due to the country's strong pharmaceutical manufacturing capabilities, adherence to international quality standards, and the availability of specialized dosage forms. Greek manufacturers often hold patents for unique formulations and possess advanced technology for producing complex drug products. While other countries like China, Germany, and the United States also supply Fentanyl formulations, Greece's competitive advantage lies in its consistent product quality, regulatory compliance, and established trade relations with India. Greece's share in India's Fentanyl import market is notable, reflecting its position as a reliable supplier.

India imports Fentanyl formulations from Greece due to the availability of specialized dosage forms and patented formulations not produced domestically. Greek manufacturers offer high-quality products that meet international standards, ensuring efficacy and safety. The importation of these formulations addresses specific medical needs in India, particularly in pain management therapies.

Compared to other origins like China, Germany, and the United States, Greece offers competitive advantages in terms of product quality, regulatory compliance, and consistency. While China may offer lower prices, concerns about quality and regulatory standards can be a deterrent. Germany and the United States provide high-quality products but may have higher costs and longer lead times. Greece's balance of quality, cost, and reliability makes it an attractive source for Fentanyl formulations.

Potential risks for Indian importers include reliance on a single source, currency fluctuations, changes in regulatory policies, quality control issues, and shipping disruptions. To mitigate these risks, importers should consider diversifying their supplier base, maintaining adequate inventory levels, and establishing robust quality assurance processes. Monitoring geopolitical developments and maintaining open communication with suppliers can also help in managing potential disruptions.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source and mitigate supply chain risks.
2. 2Inventory Planning: Maintain sufficient stock levels to buffer against potential shipping delays or supply disruptions.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Payment (DA), or Documents Against Acceptance (DP), to manage financial exposure.
4. 4Minimum Order Quantities (MOQs):